0.3307
前日終値:
$0.3306
開ける:
$0.3325
24時間の取引高:
39,928
Relative Volume:
0.07
時価総額:
$7.30M
収益:
$275.60K
当期純損益:
$-8.33M
株価収益率:
-0.716
EPS:
-0.4619
ネットキャッシュフロー:
$-5.40M
1週間 パフォーマンス:
-5.74%
1か月 パフォーマンス:
-31.41%
6か月 パフォーマンス:
-33.77%
1年 パフォーマンス:
-54.81%
Nexalin Technology Inc Stock (NXL) Company Profile
Compare NXL vs ABT, SYK, MDT, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
NXL
Nexalin Technology Inc
|
0.3312 | 7.27M | 275.60K | -8.33M | -5.40M | -0.4619 |
|
ABT
Abbott Laboratories
|
116.37 | 198.01B | 46.59B | 5.41B | 7.38B | 3.0938 |
|
SYK
Stryker Corp
|
331.42 | 130.41B | 25.27B | 3.34B | 4.57B | 8.6334 |
|
MDT
Medtronic Plc
|
93.06 | 120.48B | 36.36B | 4.84B | 5.43B | 3.7261 |
|
BSX
Boston Scientific Corp
|
50.76 | 75.37B | 20.62B | 3.56B | 3.48B | 2.3847 |
|
EW
Edwards Lifesciences Corp
|
89.89 | 53.19B | 6.30B | 1.07B | 1.09B | 1.8406 |
Nexalin Technology Inc (NXL) 最新ニュース
Nexalin Announces Capital Raise and Flexible Equity Facility - TipRanks
Nexalin Technology Raises $750,000 in Registered Direct Offering - Minichart
Nexalin Technology Announces $0.75M Direct Offering and $15M Equity Purchase Facility With Alumni Capital - TradingView
Nexalin (NXL) EPS and Revenue: EPS Does Not Reach the Reported Estimate in the Available Record; The Share Price Sheds 2.06% in Latest TradingEPS Guidance Update - dars.gov.et
Nexalin Faces New Nasdaq Equity Deficiency, Delisting Risk - The Globe and Mail
Nexalin Technology Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Nexalin Technology earnings missed, revenue fell short of estimates By Investing.com - Investing.com South Africa
Nexalin Technology earnings missed, revenue fell short of estimates - Investing.com
Nexalin Technology Inc. (NASDAQ: NXL) Share Price, NXL Stock News, NXL Share Price & Updates - Kalkine
Nexalin Technology, Inc. 2Q 2026: Revenue $12.16K, EPS ($0.11) — 10-Q Summary - TradingView
Nexalin Technology (NXL) flags going concern risk as losses mount and Nasdaq warns - Stock Titan
Nexalin Technology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Nexalin Technology | 8-K: Current report - Moomoo
Nexalin Technology Inc (NXL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Nexalin Technology Inc (NXL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Nexalin Technology Inc expected to post a loss of 10 cents a shareEarnings Preview - TradingView
Nexalin Expands and Extends Houston Headquarters Lease Commitment - The Globe and Mail
Nexalin Appeals Nasdaq Delisting Following Compliance Shortfalls - The Globe and Mail
Nexalin Technology Inc (NXL) Institutional Confidence - TradingKey
Nexalin Technology Received Notice of Delisting - TradingView
Nexalin Technology Inc (NXL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
NXL|Nexalin Technology Inc|Price:0.353|Chg%:+0.014 - TradingKey
Nexalin Technology Inc (NXL) Cash Flow - TradingKey
Nexalin Technology Inc (NXL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
NXL|Nexalin Technology Inc|Price:0.500|Chg%:+0.019 - TradingKey
Nexalin Technology Inc (NXL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Nexalin Technology Inc (NXL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
NXL|Nexalin Technology Inc|Price:0.481|Chg%:+0.013 - TradingKey
NXL Q1 2026 Earnings: EPS Misses Estimates as Company Advances Non-Invasive Neuromodulation PipelineNew Analyst Coverage - Vinanet
Nexalin Technology, Inc. Revenue Breakdown – NASDAQ:NXL - TradingView
NXL Q1 2026 Earnings: EPS Misses Estimates by 8.91% While Shares Edge HigherQuarterly Profit Report - Vinanet
NXL Q1 2026 Earnings: Loss Per Share Misses Estimates as Development Continues Without Revenue - Vinanet
Nexalin Technology (NXL) Registration filing Summary - Quartr
Nexalin Technology Announces Two Clinical Abstracts Accepted for Presentation at the 2026 NYC Neuromodulation Conference Highlighting Preliminary Clinical Results Across Anxiety, Depression, Insomnia and Quality of Life - True North Radio Network
Nexalin Technology Inc. (NXL) Q1 2026 Earnings: EPS Misses Estimates as Pre‑Revenue Biotech Advances Pipeline - dars.gov.et
Nexalin Technology Inc. (NXL) Q1 2026 Earnings: EPS Misses Estimates Amid Pre-Revenue Development Stage - dars.gov.et
Nexalin Technology (NXL) Surges Over 11% as Shares Test Key Resistance LevelATR Stop - dars.gov.et
NXL | Nexalin Technology, Inc. Common Executive Compensation - Quiver Quantitative
Nexalin Technology | ARS: Annual Report to Security Holders - Moomoo
Form DEF 14A Nexalin Technology Inc For: 10 July By Investing.com - Investing.com Nigeria
Nexalin Technology (NXL) plans new 7M-share incentive pool and reverse split authority - Stock Titan
Form DEF 14A Nexalin Technology Inc For: 10 July - Investing.com India
Nexalin Technology (NXL) Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Stage ContinuesFinal Results - DonanımHaber
Enterprise value to revenue forward of Nexalin Technology, Inc. – NASDAQ:NXL - TradingView
Price to book forward of Nexalin Technology, Inc. – NASDAQ:NXL - TradingView
Price to sales forward of Nexalin Technology, Inc. – NASDAQ:NXL - TradingView
Price to earnings forward of Nexalin Technology, Inc. – NASDAQ:NXL - TradingView
NXL Q1 2026 Earnings: EPS Misses Estimates, Stock Declines 5%Margin Compression Risk - dars.gov.et
Form PRE 14A Nexalin Technology Inc For: 29 June By Investing.com - Investing.com South Africa
Nexalin Technology (NXL) seeks shareholder votes for equity plan, reverse split - Stock Titan
NexaLine Technology Registers 1.2 Million Shares for Resale - Moomoo
Nexalin Technology Inc (NXL) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):